Baseline characteristics of the sample
| Characteristic | Value |
|---|---|
| Number of eyes/patients | 23 eyes/20 patients |
| Sex, n (%) | |
| Male | 13 (65%) |
| Female | 7 (35%) |
| Age (years) | |
| Range | 35–82 |
| Mean±SD | 62±10 |
| Type of diabetes, n (%) | |
| Type 1 | 1 (5%) |
| Type 2 | 19 (95%) |
| Duration of diabetes (years) | |
| Range | 1–27 |
| Mean±SD | 12±8 |
| HbA1c (%) | |
| Range | 6.0–11.0 |
| Mean±SD | 7.2±1.4 |
| Type of CSMO, n (%) | |
| Focal | 5 (22%) |
| Diffuse | 18 (78%) |
| Type of diabetic retinopathy, n (%) | |
| Background | 15 (65%) |
| Proliferative | 8 (35%) |
| CRT (µm) | |
| Mean±SD | 484±117 |
| Range | 401–798 |
| BCVA | |
| Mean±SD in ETDRS letters (Snellen eq.) | 44±20 (20/160) |
| Range in Snellen equivalent | CF—20/30 |
| Previous treatments, n (%) | |
| Anti-VEGF (bevacizumab) | 11 (48%) |
| Focal Laser | 6 (26%) |
| Intravitreal Steroids | 2 (8%) |
| Anti-VEGF (bevacizumab) + focal laser | 4 (17%) |
| PRP | 8 (35%) |
BCVA, best-corrected visual acuity; CF, count fingers; CRT, central retinal thickness; CSME, clinically significant macular oedema; ETDRS, Early Treatment Diabetic Retinopathy Study; PRP, panretinal photocoagulation; VEGF, vascular endothelial grow factor.